BioCardia Inc (BCDA)
NASDAQ:BCDA
Want to see BCDA full AI Analyst Report?
BCDA Stock Chart & Stats
$1.18
-$0.06(-2.59%)
At close: 4:00 PM EST
$1.18
-$0.06(-2.59%)
Day’s Range― - ―
52-Week Range$0.78 - $2.45
Previous CloseN/A
Volume12.78K
Average Volume (3M)1.15M
Market Cap
$14.39M
Enterprise Value$4.96M
Total Cash (Recent Filing)$951.00K
Total Debt (Recent Filing)$412.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 12, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding14,884,328
10 Day Avg. Volume282,453
30 Day Avg. Volume1,147,607
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.12
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.78
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$15.50Price Target Upside1213.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Japan Regulatory Support (PMDA)PMDA acceptance of existing CardiAMP trial data materially shortens Japan approval timelines and reduces need for new local efficacy trials. This durable regulatory clearance path can enable faster market access, reimbursement discussions, and a reference-country role for wider international registrations.
Defined FDA Approval Pathway (PMA)Clear FDA guidance that a single pivotal HF II trial can support a PMA reduces long-term regulatory uncertainty. A defined path enables focused trial design, predictable statistical engagement, and planning for U.S. commercialization — a structural benefit versus ambiguous regulatory routes.
Proprietary Delivery/IP (Heart3D, Helix)Patent protection for Heart3D and regulatory progress for Helix strengthen BioCardia's delivery-platform moat. Durable IP and an integrated delivery stack make the company a more attractive partner for cell/gene developers and support multiple commercial pathways beyond single-product sales.
Bears Say
Negative Equity & No Meaningful RevenueNegative equity and absent revenue reflect cumulative operating losses that materially weaken financial flexibility. This structural weakness limits ability to raise debt, increases reliance on dilutive equity financings, and heightens execution risk until meaningful commercial revenues or large partnering proceeds arrive.
High Cash Burn With Limited RunwayQuarterly cash burn far exceeds available cash, creating an ongoing financing imperative. Repeated capital raises risk dilution and can divert management focus to funding rather than operations, threatening continuity of clinical programs unless sizable non-dilutive or partnership funding is secured.
Clinical Enrollment & Execution RiskDependence on scaling enrollment across many centers creates a persistent operational bottleneck. Slow onboarding or resource-constrained enrollment can delay pivotal endpoints, postpone regulatory submissions, and increase trial costs — structurally impacting timing of any U.S. approval and commercialization.
BioCardia News
BCDA FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was $0.78 and its highest was $2.45 in the past 12 months.
What is BioCardia Inc’s market cap?
BioCardia Inc’s market cap is $14.39M.
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is Aug 12, 2026 which is in 48 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on May 15, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.165 by -$0.045.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate is -0.18.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 14,884,328 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.165. Following the earnings report the stock price went down -7.339%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in BCDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioCardia Inc
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
BCDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong clinical and regulatory progress—statistically significant blinded echocardiography results, constructive PMDA guidance in Japan, favorable FDA engagement, device pathway clarity for Helix, and reduced operating expenses. However, these positives are tempered by an immediate funding shortfall (cash of $951k), the need to complete an additional pivotal trial for U.S. approval (PMA pathway) and enrollment/resource risks for the HF II study. Management plans near-term financing in Q2 to fund the Japan submission and trial enrollment, but execution and funding risk remain material.View all BCDA earnings summariesBCDA Stock 12 Month Forecast
Average Price Target
$15.50
▲(1213.56% Upside)
Technical Analysis
Ownership Overview
13.01% Insiders
1.26% Mutual Funds
1.11% Other Institutional Investors
83.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---